|Table of Contents|

Effect of docetaxel combined with carboplatin preoperative neoadjuvant chemotherapy on short-term efficacy and peripheral blood T lymphocyte subsets in patients with locally advanced cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 15
Page:
2851-2856
Research Field:
Publishing date:

Info

Title:
Effect of docetaxel combined with carboplatin preoperative neoadjuvant chemotherapy on short-term efficacy and peripheral blood T lymphocyte subsets in patients with locally advanced cervical cancer
Author(s):
LI Wenjuan1; GUO Xue2; CHENG Xin1; QIN Shuang1; SHANG Xianping3
1.Department of Clinical Laboratory;2.Department of Health Care;3.Department of Gynecology,Jinan People's Hospital Affiliated to Shandong First Medical University,Shandong Jinan 271199,China.
Keywords:
docetaxel; carboplatin; neoadjuvant chemotherapy; locally advanced stage; cervical cancer; curative effect; T lymphocyte
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2024.15.025
Abstract:
Objective:To explore and analyze the effects of docetaxel combined with carboplatin preoperative neoadjuvant chemotherapy on the short-term efficacy and peripheral blood T lymphocyte subsets in patients with locally advanced cervical cancer.Methods:104 patients with local cervical cancer admitted to our hospital from March 2019 to March 2021 were randomly divided into group A(53 cases) and group B(51 cases).Patients in group A were treated with docetaxel+carboplatin,and patients in group B were treated with fluorouracil+carboplatin.The short-term efficacy of chemotherapy,the changes of peripheral blood T lymphocyte subsets before and after chemotherapy,serious adverse reactions of chemotherapy,and surgery-related indicators were compared between the two groups.Results:The short-term total effective rate was 71.70% in group A and 60.78% in group B.The clinical benefit rate of group A and group B was 90.57% and 88.24% respectively.There was no significant difference in the short-term total response rate and clinical benefit rate of chemotherapy between the two groups(P＞0.05).There were no significant differences in the levels of CD3+,CD4+,CD8+ and CD4+/CD8+ between two groups before chemotherapy(P＞0.05).After chemotherapy,the levels of CD3+,CD4+ and CD4+/CD8+ in two groups were significantly decreased compared with before chemotherapy(P＜0.05),and the level of CD8+ in group B was significantly increased compared with before chemotherapy(P＜0.05).After chemotherapy,the levels of CD3+,CD4+ and CD4+/CD8+ in group A were significantly higher than those in group B(P＜0.05),and the levels of CD8+ in group A were significantly lower than those in group B(P＜0.05).The incidence of serious adverse reactions in group A was significantly lower than that in group B(P＜0.05).There were no significant differences in operation time,intraoperative blood loss,pelvic lymph node metastasis rate and positive rate of vaginal incision margin between two groups(P＞0.05).Conclusion:The short-term efficacy of neoadjuvant chemotherapy with polyene paclitaxel combined with carboplatin for patients with locally advanced cervical cancer is similar to that of neoadjuvant chemotherapy with fluorouracil combined with carboplatin,but the polyene paclitaxel regimen has less effect on the immune function of patients and has a lower incidence of serious adverse reactions,which is worthy of clinical promotion.

References:

[1] MAYADEV JS,KE G,MAHANTSHETTY U,et al.Global challenges of radiotherapy for the treatment of locally advanced cervical cancer［J］.Int J Gynecol Cancer,2022,32(3):436-445.
[2] FENG CH,MELL LK,SHARABI AB,et al.Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer［J］.Semin Radiat Oncol,2020,30(4):273-280.
[3] 候丽盈,刘艳,鲁鹏,等.白蛋白结合型紫杉醇在宫颈癌新辅助化疗中的研究进展［J］.国际妇产科学杂志,2021,48(2):135-138,143. HOU LY,LIU Y,LU P,et al.Research progress of nanoparticle albumin bound paclitaxel in neoadjuvant chemotherapy for cervical cancer［J］.International Journal of Obstetrics and Gynecology,2021,48(2):135-138,143.
[4] GADDUCCI A,COSIO S.Neoadjuvant chemotherapy in locally advanced cervical cancer:Review of the literature and perspectives of clinical research［J］.Anticancer Res,2020,40(9):4819-4828.
[5] MIRIYALA R,MAHANTSHETTY U,MAHESHWARI A,et al.Neoadjuvant chemotherapy followed by surgery in cervical cancer:past,present and future［J］.Int J Gynecol Cancer,2022,32(3):260-265.
[6] 周静,江雯波,殷婵霞.卡铂联合紫杉醇作为局部晚期宫颈癌新辅助化疗的可行性和安全性研究［J］.药物生物技术,2021,28(1):61-65. ZHOU J,JIANG WB,YIN CX.The feasibility and safety of carboplatin combined with paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer［J］.Pharmaceutical Biotechnology,2021,28(1):61-65.
[7] ZHANG Y,YU M,JING Y,et al.Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer［J］.Br J Cancer,2021,124(2):414-424.
[8] 陈宝杰,杜丹,邓宇,等.106例局部晚期宫颈癌根治性同步放化疗的临床疗效及预后影响因素［J］.现代妇产科进展,2023,32(3):207-213. CHEN BJ,DU D,DENG Y,et al.Analysis of clinical efficacy and prognostic factors of radical simultaneous radiotherapy and chemotherapy in 106 patients with locally advanced cervical cancer［J］.Progress in Modern Obstetrics and Gynecology,2023,32(3):207-213.
[9] 刘超霞,冉晓敏,张克强,等.淋巴结转移的局部晚期宫颈癌行PD-1抑制剂联合同步放化疗的疗效及安全性研究［J］.中国肿瘤临床,2023,50(8):418-422. LIU CX,RAN XM,ZHANG KQ,et al.Efficacy and safety of programmed cell death-1 inhibitor combined with concurrent chemoradiotherapy for locally advanced cervical cancer patients with lymph node metastases［J］.Chinese Journal of Oncology,2023,50(8):418-422.
[10]MENG X,CHU Y,PAN Y,et al.Preoperative neoadjuvant chemotherapy combined with radical surgery in cervical cancer［J］.J BUON,2020,25(1):125-131.
[11]BUDA A,BORGHESE M,PUPPO A,et al.Neoadjuvant chemotherapy prior fertility-sparing surgery in women with FIGO 2018 stage IB2 cervical cancer:A systematic review［J］.Cancers(Basel),2022,14(3):797.
[12]蒋清华,陈月梅,张仁静.中晚期宫颈癌同步放化疗患者症状群困扰及其与生活质量的相关性研究［J］.重庆医学,2023,52(2):225-229,234. JIANG QH,CHEN YM,ZHANG RJ.Study on symptom cluster distress and its correlation with quality of life in patients with middle and advanced cervical cancer undergoing concurrent chemoradiotherapy［J］.Chongqing Medical University,2023,52(2):225-229,234.
[13]杨柳,张明坤,季福庆,等.HER-2阳性乳腺癌新辅助化疗疗效影响因素分析及相关预后模型的构建［J］.现代肿瘤医学,2023,31(11):2037-2041. YANG L,ZHANG MK,JI FQ,et al.The analysis of the factors affecting pathological complete response of HER-2 positive breast cancer patients after neoadjuvant chemotherapy and the construction of related model［J］.Modern Oncology,2023,31(11):2037-2041.
[14]闫帅，潘茜茜，陶维阳.乳腺癌新辅助治疗策略的研究进展［J］.现代肿瘤医学，2021,29(06):1083－1087. YAN S,PAN XX,TAO WY.Research progress of neoadjuvant therapy strategies for breast cancer［J］.Modern Oncology,2021,29(06):1083－1087.
[15] 韩蜜,伍梦玲,龙远雄,等.顺铂治疗鼻咽癌耐药机制与逆转策略研究进展［J］.医药导报,2023,42(10):1529-1533. HAN M,WU ML,LONG YX,et al.Advanced pesearch progress of cisplatin resistance mechanism and reversal strategy in nasopharyngeal carcinoma chemotherapy［J］.Medical News Guide,2023,42(10):1529-1533.
[16] 上官梦原,赵菁,杨艳荣,等.五味子脂A联合卡铂对人卵巢癌Skov3细胞增殖、迁移和侵袭的抑制作用及其机制［J］.吉林大学学报（医学版）,2018,44(2):292-298. SHANGGUAN MY,ZHAO J,YANG YR,et al.Inhibitory effects of gomisin A combined with carboplatin on proliferation,invasion and metastasis of human ovarian cancer Skov3 cells and their mechanisms［J］.Journal of Jilin University(Medical Edition),2018,44(2):292-298.
[17] 马宁珠,王振霖,张建国,等.RGD和泊洛沙姆F127共修饰载多西紫杉醇脂质体的制备及体外抗卵巢癌的初步研究［J］.中南药学,2023,21(5):1196-1202. MA NZ,WANG ZL,ZHANG JG,et al.Preparation of docetaxel-loaded liposomes co-modified by RGD and poloxamer F127 and preliminary study on anti-ovarian cancer in vitro［J］.Pharmacy of Central South,2023,21(5):1196-1202.
[18] MA Z,ZHANG W,DONG B,et al.Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy［J］.Theranostics,2022,12(11):4965-4979.
[19] YU Z,TANG H,CHEN S,et al.Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy［J］.Drug Resist Updat,2023,67(11):100915.
[20] 张瑜,刘会佳,金晨望,等.腹腔5-氟尿嘧啶缓释剂包裹植入物的CT表现［J］.实用放射学杂志,2023,39(9):1457-1461. ZHANG Y,LIU HJ,JIN CW,et al.CT findings of sustained-release 5-fluorouracil enwrapped implants in abdominal cavity［J］.Journal of Practical Radiology,2023,39(9):1457-1461.
[21] 胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较［J］.中国药房,2016,27(24):3353-3356. HU YQ,ZHANG YB,WANG H,et al.Comparison of efficacy and safety of docetaxel combined with carboplatin and paclitaxel and cisplatin in the treatment of advanced ovarian cancer［J］.Chinese Pharmacy,2016,27(24):3353-3356.

Memo

Memo:
山东省医药卫生科技发展计划项目(编号：202105010536)
Last Update: 2024-06-28